We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
EyePoint Inc
EYPT
$978M
| $4.71M | 0.02% |
500,335
| – | – |
|
577
Idexx Laboratories
IDXX
$46.4B
| $4.67M | 0.02% |
+8,699
| New | +$4.16M |
|
578
Kimberly-Clark
KMB
$37B
| $4.63M | 0.02% |
+35,892
| New | +$4.87M |
|
579
Fidelity National Information Services
FIS
$22.9B
| $4.63M | 0.02% |
56,832
+54,064
| +1,953% | +$4.21M |
|
|
BRDG
580
DELISTED
Bridge Investment Group
BRDG
| $4.6M | 0.02% |
460,000
+21,948
| +5% | +$205K |
|
581
Reinsurance Group of America
RGA
$15.5B
| $4.56M | 0.02% |
22,987
-145,488
| -86% | -$28.4M |
|
582
Valero Energy
VLO
$88.9B
| $4.55M | 0.02% |
33,879
+7,132
| +27% | +$889K |
|
583
Public Service Enterprise Group
PEG
$38B
| $4.54M | 0.02% |
53,976
+11,883
| +28% | +$958K |
|
|
XOMA
584
DELISTED
Xoma
XOMA
| $4.54M | 0.02% |
180,230
+11,680
| +7% | +$280K |
|
585
Ross Stores
ROST
$80.5B
| $4.54M | 0.02% |
35,569
+7,694
| +28% | +$1.07M |
|
586
Eledon Pharmaceuticals
ELDN
$269M
| $4.53M | 0.02% |
1,671,822
| – | – |
|
587
CBRE Group
CBRE
$43.7B
| $4.45M | 0.02% |
31,764
+6,792
| +27% | +$859K |
|
|
ORKA
588
Oruka Therapeutics
ORKA
$5.92B
| $4.38M | 0.02% |
390,904
+100
| +0% | +$1.04K |
|
589
Riot Platforms
RIOT
$8.15B
| $4.36M | 0.02% |
385,565
-423,209
| -52% | -$3.6M |
|
|
SRDX
590
DELISTED
Surmodics
SRDX
| $4.31M | 0.02% |
+144,977
| New | +$4.18M |
|
591
Forte Biosciences
FBRX
$1.57B
| $4.29M | 0.02% |
331,987
+127,165
| +62% | +$1.09M |
|
592
Xcel Energy
XEL
$48.6B
| $4.25M | 0.02% |
62,387
+13,872
| +29% | +$962K |
|
593
Dave & Buster's
PLAY
$369M
| $4.25M | 0.02% |
141,162
-18,494
| -12% | -$417K |
|
594
Aurinia Pharmaceuticals
AUPH
$1.92B
| $4.24M | 0.02% |
500,416
| – | – |
|
595
Biohaven
BHVN
$2.07B
| $4.24M | 0.02% |
300,389
-300,060
| -50% | -$5.35M |
|
596
Charter Communications
CHTR
$18.3B
| $4.22M | 0.02% |
+10,324
| New | +$3.95M |
|
597
UroGen Pharma
URGN
$1.94B
| $4.2M | 0.02% |
306,724
+353
| +0.1% | +$3.39K |
|
598
Humacyte
HUMA
$192M
| $4.18M | 0.02% |
2,001,393
-1,948,607
| -49% | -$3.74M |
|
599
Devon Energy
DVN
$50.8B
| $4.13M | 0.02% |
129,733
+13,953
| +12% | +$444K |
|
600
Baker Hughes
BKR
$61.3B
| $4.11M | 0.02% |
107,168
+23,518
| +28% | +$887K |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.